5 citations
,
February 2025 in “Pediatric Dermatology” Ritlecitinib was generally well tolerated in children with alopecia areata.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
Cetirizine-loaded gel may effectively promote hair growth in alopecia.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
9 citations
,
February 2019 in “BMC cancer” M30 is a promising treatment for preventing hair loss during chemotherapy.
56 citations
,
September 2016 in “Pharmaceutical Research” The fish oil-based gel with imiquimod improves skin cancer treatment and reduces inflammation.
32 citations
,
March 2018 in “Neoplasia” Nephronectin is linked to worse breast cancer outcomes and helps cancer spread.
22 citations
,
November 2020 in “Frontiers in Physics” Proton minibeam radiotherapy shows promise for sparing healthy tissue in cancer treatment but needs further research and technological development.
14 citations
,
January 2005 in “Pediatric Dermatology” UVA1-light therapy successfully treated a child's skin condition, mycosis fungoides.
3 citations
,
February 2023 in “BMJ Case Reports” OnabotulinumtoxinA treatment improved hair-pulling disorder and hair regrowth in a woman with chronic migraines.
5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
4 citations
,
March 2008 in “Journal of the American Academy of Dermatology” October 2025 in “Australasian Journal of Dermatology” Bimekizumab effectively treated a man's chronic beard hair loss.
4 citations
,
January 2018 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Panitumumab can cause excessive ear hair growth.
January 2016 in “Refubium (Universitätsbibliothek der Freien Universität Berlin)” CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.
1 citations
,
March 2019 in “Actas Dermo-Sifiliográficas” New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.
5 citations
,
January 2024 in “Journal of Cancer” The treatment combination is effective and generally safe for lung cancer.
NB-UVB phototherapy is an effective and safe treatment for vitiligo, especially on hands and feet, and can be improved with tacrolimus.
215 citations
,
March 2011 in “Clinical Cancer Research” Sorafenib is effective in treating Desmoid Tumor/Deep Fibromatosis.
2 citations
,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
5 citations
,
June 2005 in “Journal of Clinical Oncology” PPX causes much less hair loss than traditional taxanes.
November 2025 in “ACS Nano” The microreactor effectively fights antibiotic-resistant infections and promotes tissue healing.
3 citations
,
July 2025 in “International Immunopharmacology”
5 citations
,
January 2022 in “Proceedings of the Pakistan Academy of Sciences B Life and Environmental Sciences” Nanoparticles improve cancer treatment by reducing side effects and targeting cancer cells better.
1 citations
,
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.
3 citations
,
February 2023 in “Journal of drug delivery science and technology” The new drug carriers show promise for better targeting and treating ovarian cancer.
7 citations
,
December 2022 in “Skin Appendage Disorders” Certolizumab effectively treats psoriasis and psoriatic arthritis with fewer side effects than adalimumab.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
2 citations
,
April 2018 in “Journal of Investigative Dermatology” Intralesional chemotherapy with 5-fluorouracil and methotrexate may worsen keratoacanthoma-type skin cancer in transplant patients.